Adjunctive intermittent theta-burst stimulation for first-episode schizophrenia: A randomized clinical trial.

Psychiatry ResMay 28, 2026 (epub)
Clinical ResearchPsychiatry

Kun Zhang, Hua Xue, Chaomin Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy of adjunctive intermittent theta-burst stimulation (iTBS) in 100 first-episode schizophrenia patients receiving risperidone and cognitive behavioral therapy (CBT). The iTBS group demonstrated a significant reduction in PANSS total scores compared to controls, with a mean difference of -13.3 at 3 months and a responder rate of 76% versus 48%.

Key findings

  • iTBS group had a mean PANSS reduction of -13.3 at 3 months compared to controls.
  • Responder rate was significantly higher in the iTBS group at 76% versus 48%.
  • Cognitive function improvements were significant across all domains in the iTBS group.
  • Post-treatment, iTBS group showed higher GDNF and lower cortisol and DHEA-S levels.

Why it matters

The findings suggest that adjunctive iTBS may enhance treatment outcomes in first-episode schizophrenia, potentially leading to improved symptom management and cognitive function. Understanding the role of biomarkers could also inform future treatment strategies.

Source

PubMed · PMID 42308997

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.